Combination of Imaging Methods Improves Diagnostics
The new method serves to improve the use of imaging in the diagnostic process, according to researchers from the Helmholtz Zentrum München and the Technische Universität München. Results of the study are published in the "Angewandte Chemie International Edition" journal.
MRI offers a high-resolution procedure for the diagnostic imaging of patients. Often this procedure additionally uses contrast agents that clarify certain tissue structures and pathological processes. However, the image signal that is generated in the MRI does not correlate with the actual quantitative concentration of contrast agent in the tissue.
The researchers, led by Prof. Dr. Axel Walch and Dr. Michaela Aichler from the Helmholtz Zentrum München, developed the MALDI-MS imaging technique to make it possible specifically to measure contrast agent concentrations. This new technique enabled the research team to obtain quantitative data on the gadolinium-based contrast agents in the tissue and also in establishing a corresponding correlation with the MRI image.
MALDI-MS imaging is a form of molecular imaging in tissues at a microscopic level. Using the mass signals, it can detect and localise a wide range of molecules, such as proteins, lipids and components of cell metabolism, as well as substances and their metabolites in tissue sections.
The researchers worked with scientists headed by Dr. Moritz Wildgruber from the Technische Universität München's Klinikum rechts der Isar to conduct the successful testing of the new technique.
The procedure is already being used at the Helmholtz Zentrum München and in industry for research into active substances, the research team says.
The current study has now made MRI contrast agents available as a new class of molecules for this method. "By precisely and quantitatively registering the histological distribution of contrast agents, we can make a crucial contribution to the further development and improvement of these substances," Prof. Walch explains.
This research work was supported by the Ministry of Education and Research of the Federal Republic of Germany (BMBF) (Grant Nos. 01IB10004E, 01ZX1310B), the Deutsche Forschungsgemeinschaft (Grant Nos. HO 1258/3-1, SFB 824 TP Z02, and WA 1656/3-1) to Prof. Walch, and Deutsche Forschungsgemeinschaft (Grant WI 3686/4-1) to Dr. Wildgruber.
Source: Helmholtz Zentrum Muenchen - German Research Centre for Environmental Health
Image Credit: Northwestern Lake Forest Hospital
Published on : Sat, 21 Feb 2015
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850’s fundamental performance has been refined...
We recognize that the best chance any patient has at getting better is a clinician at their bedside with all the right answers and the confidence to act. SonoSite education and training is the industry standard – no other point-of-care ultrasound manufacturer...
Redefining the Vision of Cardiovascular The LISENDO 880 is Hitachi’s premium 2D/4D diagnostic ultrasound solution for cardiologists in any clinical setting. The LISENDO 880 platform is redefining the vision for cardiac ultrasound by providing exceptional...
Superb Low Dose CT SCENARIA View continues its evolution for doctors, operators and patients, driving you ahead with a superb low dose CT. Hitachi’s Intelli IPV technology with Visual Modeling enables both, significant noise and dose...
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...